Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents

Cytokine
M Teresa CibeiraJoan Bladé

Abstract

An increased bone marrow (BM) angiogenesis is associated with poor outcome in multiple myeloma (MM). Angiogenesis study in MM treated with novel antimyeloma agents: thalidomide, lenalidomide, bortezomib, and with dexamethasone. Forty-four patients with MM (14 newly diagnosed, 30 refractory/relapsed) were treated with novel agents at our institution. A BM biopsy was obtained before the initiation of therapy in 19. Angiogenesis was assessed by microvessel density (MVD) estimation in BM biopsies stained with the monoclonal anti-CD34 antibody, and by serum levels of angiogenic factors (VEGF, bFGF, and HGF) and cytokines (IL-6 and TNF-alpha). A positive correlation was found between BM plasma cell involvement and MVD estimation (p=0.01). However, MVD was not significantly correlated with either disease phase (p=0.065) or response to therapy (p=0.79). Neither baseline serum levels of angiogenic cytokines correlated to response to treatment. No significant correlation was found between BM MVD and serum levels of angiogenic cytokines. Serum levels of angiogenic cytokines before and after therapy showed a significant increase of bFGF (p=0.008). There is no relationship between MVD estimation and baseline serum levels of angiogenic cytok...Continue Reading

References

Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Jul 1, 1994·British Journal of Haematology·A VaccaF Dammacco
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Nov 24, 1999·The New England Journal of Medicine·N Raje, K Anderson
Feb 13, 2001·European Journal of Haematology·M LarocheM Attal
Dec 12, 2001·Seminars in Oncology·J Folkman
Jan 31, 2002·Annual Review of Medicine·Paul RichardsonKenneth Anderson
Mar 12, 2002·British Journal of Haematology·Tsuyoshi IwasakiEizo Kakishita
Oct 24, 2002·Blood·Shaji KumarS Vincent Rajkumar
Nov 20, 2002·British Journal of Haematology·Shaji KumarS Vincent Rajkumar
May 20, 2004·Cytokine·Laura RosiñolEmili Montserrat
Jan 11, 2005·British Journal of Haematology·Niels Frost AndersenNiels Abildgaard
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jul 20, 2005·Best Practice & Research. Clinical Haematology·Teru HideshimaKenneth C Anderson
Oct 11, 2005·Mayo Clinic Proceedings·S Vincent Rajkumar, Robert A Kyle
Nov 1, 2005·Expert Opinion on Investigational Drugs·Maurizio ZangariGuido Tricot
Dec 17, 2005·Leukemia·A Vacca, D Ribatti
Jan 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart BarlogieJohn C Crowley
Jun 27, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Christian JakobOrhan Sezer
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiJean-Luc Harousseau

❮ Previous
Next ❯

Citations

Jul 8, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Nicola GiulianiSabrina Bonomini
Feb 24, 2009·Archives of Physiology and Biochemistry·Eline MenuKarin Vanderkerken
Jun 12, 2010·American Journal of Hematology·Giovanni BarosiUNKNOWN Myeloproliferative Research Consortium
Apr 22, 2016·Current Opinion in Hematology·Salomon ManierIrene M Ghobrial
May 8, 2015·Expert Review of Anticancer Therapy·Junya KurodaMasafumi Taniwaki
Jun 11, 2020·Journal of Clinical Medicine·Roberto RiaAngelo Vacca
Jul 14, 2018·International Journal of Molecular Sciences·Domenico Ribatti, Angelo Vacca

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.